KR20240110801A - 신장 질환의 치료 - Google Patents

신장 질환의 치료 Download PDF

Info

Publication number
KR20240110801A
KR20240110801A KR1020247015819A KR20247015819A KR20240110801A KR 20240110801 A KR20240110801 A KR 20240110801A KR 1020247015819 A KR1020247015819 A KR 1020247015819A KR 20247015819 A KR20247015819 A KR 20247015819A KR 20240110801 A KR20240110801 A KR 20240110801A
Authority
KR
South Korea
Prior art keywords
patient
egfr
approximately
injection
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247015819A
Other languages
English (en)
Korean (ko)
Inventor
티모시 에이. 버트람
디팍 자인
Original Assignee
티모시 에이. 버트람
디팍 자인
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 티모시 에이. 버트람, 디팍 자인 filed Critical 티모시 에이. 버트람
Publication of KR20240110801A publication Critical patent/KR20240110801A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
KR1020247015819A 2021-10-14 2022-10-14 신장 질환의 치료 Pending KR20240110801A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163255885P 2021-10-14 2021-10-14
US63/255,885 2021-10-14
US202263307801P 2022-02-08 2022-02-08
US63/307,801 2022-02-08
US202263321204P 2022-03-18 2022-03-18
US63/321,204 2022-03-18
PCT/US2022/078153 WO2023064925A1 (en) 2021-10-14 2022-10-14 Treatment of kidney disease

Publications (1)

Publication Number Publication Date
KR20240110801A true KR20240110801A (ko) 2024-07-16

Family

ID=85988933

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247015819A Pending KR20240110801A (ko) 2021-10-14 2022-10-14 신장 질환의 치료

Country Status (8)

Country Link
US (1) US20250009803A1 (https=)
EP (1) EP4415729A4 (https=)
JP (1) JP2024536479A (https=)
KR (1) KR20240110801A (https=)
AU (1) AU2022362077A1 (https=)
CA (1) CA3233866A1 (https=)
MX (1) MX2024004355A (https=)
WO (1) WO2023064925A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106530A1 (en) * 2023-11-13 2025-05-22 Butler Emily Characteristics of enriched heterogeneous renal cell populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020266168A1 (en) * 2019-05-02 2021-12-02 ProKidney IPCo, LLC Treatment of kidney disease in subjects with kidney and/or urinary tract anomalies

Also Published As

Publication number Publication date
WO2023064925A1 (en) 2023-04-20
US20250009803A1 (en) 2025-01-09
JP2024536479A (ja) 2024-10-04
CA3233866A1 (en) 2023-04-20
EP4415729A4 (en) 2025-08-27
WO2023064925A8 (en) 2024-04-11
AU2022362077A1 (en) 2024-05-02
EP4415729A1 (en) 2024-08-21
MX2024004355A (es) 2024-06-21

Similar Documents

Publication Publication Date Title
EP3294356B1 (en) Compositions comprising mesenchymal stem cells and uses thereof
WO2014075589A1 (zh) 一种间充质干细胞注射液及其制备方法和在制备治疗糖尿病药物中的应用
US12350292B2 (en) Bioactive renal cells for the treatment of chronic kidney disease
US20120276067A1 (en) Assay for the Prediction of Therapeutic Effectiveness of Mesenchymal Stromal Cells, and Methods of Using Same
CN114206107A (zh) 用于产生肝细胞的方法和组合物
DE102017002458A1 (de) Von adipösem gewebe stammende stromale stammzellen zur verwendung bei der behandlung behandlungsresistenter komplexer perianalfisteln bei morbus crohn
EP3733196B1 (en) Pharmaceutical composition comprising an altered peptide ligand (apl) type peptide
Khalili et al. Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period
JPH0449246A (ja) 賢疾患治療剤
CN113677790B (zh) 用于治疗慢加急性肝衰竭的成体肝祖细胞
KR20190065245A (ko) 만성 신장 질환의 치료를 위한 생체활성 신장 세포
Kramer et al. Clinical and histologic indications for extensive pancreatic resection in nesidioblastosis
Scott-Emuakpor et al. Role of oral retinoids in treatment of acne vulgaris with a bioinformatics-based perspective of personalized medicine
KR20240110801A (ko) 신장 질환의 치료
WO2018220442A2 (en) Stromal stem cell therapeutics and methods of use
TW202100171A (zh) 用於治療非酒精性脂肪肝疾病的成人肝臟前驅細胞
CN114390925A (zh) 治疗具有肾脏和/或尿路异常的受试者的肾病
HK40113884A (zh) 肾脏疾病的治疗
CN118354777A (zh) 肾脏疾病的治疗
US20250242080A1 (en) Novel method to alter the proteome of a diseased heart by injection of ecm particles produced from decellularized 3d microtissues of human mesenchymal stem cells
CA3086280C (en) Pharmaceutical composition comprising an apl peptide
Suzuki et al. Nodular glomerulosclerosis of unknown origin associated with the nephrotic syndrome
WO2022143905A1 (zh) 一种治疗糖尿病的药物及其方法
Irazabal et al. Mesenchymal Stem Cell–Based Therapy for Chronic Kidney Disease
WO2021220216A1 (en) Methods for clearing vitreous hemorrhage

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000